Glioblastoma, a devastating and aggressive form of brain cancer, has long presented a formidable challenge to medical science. Characterized by its rapid growth and invasive nature, glioblastoma tumors possess a remarkable ability to resist conventional treatments like radiation and chemotherapy. This inherent resilience has historically limited significant advancements in patient outcomes, making the search for new therapeutic strategies a critical and ongoing endeavor. Now, researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have unveiled a promising new avenue of research, identifying a protein named SET as a potential key to unlocking glioblastoma’s defenses and making these tumors more susceptible to established therapies.
This groundbreaking discovery, published in the May 2026 issue of Cancer Letters, does not aim to replace current treatment modalities but rather to augment their effectiveness. The research team’s preclinical investigations have demonstrated that by suppressing the SET protein, the development of glioblastoma tumors could be significantly hindered. This approach represents a strategic shift, focusing on bolstering the efficacy of existing treatments rather than seeking entirely novel agents that might face similar resistance challenges.
Unveiling a Critical Weakness in Glioblastoma
The OSUCCC – James research team embarked on an extensive examination of various proteins within glioblastoma cells, searching for vulnerabilities that could be exploited. Among the multitude of proteins analyzed, SET emerged as a particularly compelling target. The profound impact observed when SET was blocked – its strong effect on tumor formation – distinguished it from other proteins investigated. Further experiments revealed an even more significant finding: interfering with SET and related proteins not only impeded tumor growth but also markedly increased the sensitivity of glioblastoma cells to radiation therapy.
These combined findings strongly suggest the existence of a specific biological pathway that, once targeted with pharmacological agents, could potentially disarm glioblastoma’s formidable defenses. This pathway is intricately linked to the regulation of cellular signals that cancer cells, including glioblastoma, exploit to fuel their relentless growth, ensure their survival, and recover from the damage inflicted by treatments.
The OSUCCC – James team’s focus honed in on a crucial enzyme known as PP2A (Protein Phosphatase 2A). PP2A plays a vital role in cellular signaling, influencing processes such as cell growth, survival, and the cellular response to therapeutic interventions. Glioblastoma cells, however, have developed sophisticated mechanisms to disrupt the normal functioning of PP2A. The research identified three key proteins – ANP32A, CIP2A, and SET – that glioblastoma cells utilize to interfere with PP2A. When the researchers experimentally blocked the activity of these proteins in laboratory settings and in animal models, a notable decrease in cancer cell survival was observed. Crucially, the surviving cancer cells exhibited a heightened vulnerability to radiation, indicating a synergistic effect when PP2A’s activity was restored.
Dr. Arnab Chakravarti, MD, chair of radiation oncology at the OSUCCC – James and a lead investigator on the study, articulated the significance of these findings: "Glioblastoma is hard to treat because it can adapt and survive. Our findings suggest that restoring PP2A activity may make glioblastoma cells less able to survive treatment. That gives us a clear path to test whether this approach can make radiation and chemotherapy more effective for patients with GBM." This statement underscores the potential of targeting this specific pathway to overcome the adaptive nature of glioblastoma, a characteristic that has long frustrated oncologists.
Charting a Course for Restoring PP2A Activity
The current research represents a crucial initial step, and it is important to emphasize that these findings are preliminary and have not yet been evaluated in human patients. Nevertheless, the implications are substantial, propelling the research into its next critical phase. The team is actively investigating the feasibility and safety of targeting SET or other proteins that act as PP2A suppressors. The ultimate goal is to determine if such targeted interventions can indeed enhance the effectiveness of standard glioblastoma therapies, such as radiation and chemotherapy.
In a parallel line of inquiry, the researchers also explored the potential of existing pharmaceutical agents. Their investigation included an FDA-approved antipsychotic drug known for its ability to increase PP2A activity. The positive results from this exploration offer further compelling evidence to pursue medications that can modulate this vital cellular pathway. However, it is imperative to reiterate that this particular drug is not currently approved or ready for use as a glioblastoma treatment. Patients should not consider using it for this purpose outside of a rigorously controlled clinical trial.
Dr. Chakravarti further elaborated on the significance of this early-stage research: "This is an important first step. By understanding how SET and related PP2A blockers help GBM survive treatment, we can test ways to block that protection and make current therapies more effective." This sentiment highlights the methodical and evidence-based approach of the research, building upon fundamental biological understanding to develop practical therapeutic strategies.
Laying the Foundation for Novel Treatment Strategies
The publication of this study in Cancer Letters in May 2026 marks a significant milestone in the ongoing battle against glioblastoma. The research was generously supported by grants from esteemed institutions, including the National Institutes of Health (NIH), the National Cancer Institute (NCI), and The Ohio State University Comprehensive Cancer Center itself, underscoring the recognized importance and potential impact of this work.
The historical context of glioblastoma treatment reveals a persistent challenge. For decades, the standard of care has revolved around surgical resection, followed by radiation therapy and concurrent chemotherapy, often with temozolomide. While these treatments can offer some patients a temporary reprieve, the median survival rate for glioblastoma patients has remained distressingly low, often in the range of 12-15 months. This grim statistic is largely attributable to the tumor’s aggressive infiltration into surrounding brain tissue, making complete surgical removal impossible, and its profound resistance to the cytotoxic effects of radiation and chemotherapy. Glioblastoma cells are adept at activating DNA repair mechanisms and evading programmed cell death, allowing them to survive and proliferate even under intense therapeutic pressure.
The discovery of the SET protein’s role in glioblastoma’s resilience offers a potential paradigm shift. By targeting SET and other PP2A-inhibiting proteins, researchers aim to create an environment where glioblastoma cells are fundamentally less capable of defending themselves against conventional treatments. This could translate into more durable responses, longer progression-free survival, and ultimately, improved quality of life and extended survival for patients.
The implications of this research extend beyond immediate therapeutic applications. A deeper understanding of the intricate molecular mechanisms by which glioblastoma evades treatment could pave the way for the development of novel diagnostic tools or biomarkers that could identify patients most likely to benefit from specific combination therapies. Furthermore, this research contributes to the broader scientific understanding of cancer cell survival strategies, potentially informing therapeutic approaches for other recalcitrant cancers.
The timeline for translating these preclinical findings into clinical practice is inherently long and complex. Rigorous clinical trials, involving multiple phases, are required to establish both the safety and efficacy of any new treatment strategy in human patients. Phase I trials typically focus on safety and dosage, Phase II trials assess efficacy and side effects, and Phase III trials compare the new treatment to existing standards of care. Each phase is critical in ensuring that potential new therapies are both beneficial and safe for patients.
While the path forward is challenging, the identification of SET as a potential therapeutic target represents a beacon of hope for glioblastoma patients and their families. It exemplifies the power of dedicated scientific inquiry to unravel the complexities of devastating diseases and to forge new pathways toward more effective treatments. The ongoing work at OSUCCC – James underscores a commitment to relentless innovation in the fight against cancer, offering a tangible prospect of improving outcomes for those diagnosed with this formidable illness.
